Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

NCT02623010 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Central Nervous System Lymphoma

Interventions

DRUG: Imbruvica

Sponsor

Rabin Medical Center

Collaborators

[object Object]